Greaves Cotton Fund Raise of ₹530 Cr

Greaves Cotton Earnings Call Transcript: Key Takeaways

Greaves Cotton reported strong revenue growth but significant margin pressure from persistent input cost inflation. Profitability was hit by non-recurring impairment charges and accelerated amortization.

Greaves Cotton Results Update

Greaves Cotton issued a Q2 FY27 press release reporting strong consolidated revenue and EBITDA growth. Core and electric mobility investee GEML drove the gains.

Greaves Cotton Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue up 44% YoY; core revenue ₹768 Cr (+24%) with EBITDA margin down to 11.5% from 14.8%. GEML revenue ₹410 Cr (+106%), EBITDA loss narrowed to ₹24 Cr.

Greaves Cotton Board Meeting Outcome

Greaves Cotton confirmed its Board met on October 29, 2026, on unaudited half-year results. No new financial figures are disclosed in this filing.

Greaves Cotton Q2 FY27 Results: Net Loss of ₹29.8 Cr

Greaves Cotton Ltd approved its standalone and consolidated unaudited results for the quarter and half year ended 30 September 2026. The Board endorsed the figures reviewed by the Audit Committee and the statutory auditors.

Key figure

Net loss ₹29.8 Cr

Greaves Cotton Board Meeting Date

Greaves Cotton Limited has scheduled a board meeting for 29th October, 2026, to consider and approve its unaudited financial results for the quarter and half-year ended September 2026.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.